In 2020, Medicare spent the most on Eliquis, with more than 2.6 million Medicare Part D enrollees taking the blood thinner at a cost of nearly $10 billion, according to data released March 8 by the AARP.

The average list price of the 75 brand-name drugs Medicare spends the most rose 5.2% in January 2022, according to AARP.

“Brand name drug prices have been rising faster than general inflation for more than a decade, forcing increasing numbers of patients to go without needed drugs,” the AARP researchers said. “Medicare beneficiaries, who have a median annual income of just under $30,000, take an average of four to five prescription drugs each month, and public opinion polls have consistently found that many skip doses or are not refilling their prescriptions because of the cost.”

AARP’s current campaign, Fair Rx Prices Now, urges lawmakers to allow Medicare to negotiate prices with pharmaceutical manufacturers, impose tax penalties on drugmakers who raise prices by more than inflation, and to cap Part D disbursements.

Here are the 10 drugs Medicare spent the most money on in 2020 that rose in price in January 2022:

1. Equip

Use: Anticoagulant for people with atrial fibrillation

Health insurance expenditure 2020: $9.9 billion

Number of beneficiaries: 2,641,941

Price increase 2022: 6 percent

2. Revlimid

Use: Cancer treatment

2020 Medicare spending: $5.4 billion

Beneficiaries: 43,747

Price increase 2022: 4.5%

3. xarelto

Use: Anticoagulant for people with atrial fibrillation

Health insurance expenditure 2020: $4.7 billion

Beneficiaries: 1,184,718

Price increase 2022: 4.9%

4. Januvia

Use: Treatment of diabetes

Health insurance expenditure 2020: $3.9 billion

Beneficiaries: 934 686

Price increase 2022: 5 percent

5. Trulicity

Use: Treatment of diabetes

Health insurance expenditure 2020: $3.3 billion

Beneficiaries: 497 327

Price increase 2022: 5 percent

6. Imbruvic

Use: Cancer treatment

Health insurance expenditure 2020: $3 billion

Beneficiaries: 26,847

Price increase 2022: 7.4%

7. gardening

Use: Treatment of diabetes

Health insurance expenditure 2020: $2.4 billion

Beneficiaries: 594 859

Price increase 2022: 4 percent

8. Humira Pen (Cf)

Use: Rheumatoid arthritis, treatment of plaque psoriasis

Health insurance expenditure 2020: $2.2 billion

Beneficiaries: 42,406

Price increase 2022: 7.4%

9. Ibrance

Use: Cancer treatment

Health insurance expenditure 2020: $2.1 billion

Beneficiaries: 21,394

Price increase 2022: 6.9%

ten. Symbicort

Use: Treatment of asthma

Health insurance expenditure 2020: $2 billion

Beneficiaries: 1,017,530

Price increase 2022: 2 percent